Search Results 1161-1170 of 21807 for Secondary

  1. Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL - Mayo Clinic

    Have a total bilirubin level ≤1.5 × ULN (unless secondary to Gilbert syndrome, hemolysis, or leukemia). Have acceptable coagulation status: Activated ...

  2. Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer - Mayo Clinic

    ... secondary to hysterectomy) AND with a documented estradiol level in the postmenopausal range according to local institutional/laboratory standards, or a ...

  3. PGY-2 Pharmacy Residency in Internal Medicine at Mayo Clinic Hospital — Rochester - Application Process

    Secondary Navigation. Overview · Application Process · Curriculum · Curriculum Overview · Medical Emergency Response and QI · Professional Development ...

  4. Publications - Grace M. Arteaga, M.D. - Mayo Clinic

    ... Secondary Analysis of Pre- Vs. Post-Implementation Data From 2017. Pediatr Crit Care Med. 2026 Jan 1; 27 (1):72-81 Epub 2025 Nov 27. View PubMed; Maloney LM ...

  5. Fellow Life - Neuro-Oncology Fellowship (Arizona) - Mayo Clinic College of Medicine & Science

    NeuroOncology Fellowship (Arizona) Fellow Life. Secondary Navigation. Overview · Application Process · Curriculum · Meet The Faculty · Fellow Life · Alumni.

  6. PGY-2 Pharmacy Residency in Ambulatory Care at Mayo Clinic Health System — Mankato - Department and Faculty

    Secondary Navigation. Overview · Application Process · Curriculum · Curriculum Overview · Professional Development · Research · Teaching and Learning ...

  7. Mayo Clinic Q and A: Understanding burning mouth syndrome

    Secondary burning mouth syndrome means your health care provider has found an underlying cause of your discomfort. Some of the potential triggers of burning ...

  8. A Study to Evaluate Tazemetostat and Pembrolizumab to Treat Advanced Urothelial Carcinoma - Mayo Clinic

    Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with MK-3475 and tazemetostat, ...

  9. Neurology - Clinical trials - Mayo Clinic

    ... secondary myelofibrosis (MF) displaying mutated calreticulin (muCALR); (3) Cohort 3 focuses on glioblastoma multiforme (GBM) which often displays the ...

  10. An Efficacy and Safety Study of Decitabine (DACOGEN) Plus Talacotuzumab (JNJ-56022473; Anti CD123) Versus Decitabine (DACOGEN) Alone in Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy - Mayo Clinic

    De novo or secondary acute myeloid leukemia (AML) (post myelodysplastic syndrome [MDS] or myeloproliferative neoplasm [MPN] or after leukemogenic ...